Canesten 500 mg / 10 mg/ g Norge - norsk - Statens legemiddelverk

canesten 500 mg / 10 mg/ g

bayer ab - solna - klotrimazol - krem, vaginalkapsel, myk - 500 mg / 10 mg/ g

Canesten 10 mg/ g / 100 mg Norge - norsk - Statens legemiddelverk

canesten 10 mg/ g / 100 mg

bayer ab - solna - klotrimazol - krem, vaginaltablett - 10 mg/ g / 100 mg

Canesten 100 mg Norge - norsk - Statens legemiddelverk

canesten 100 mg

bayer ab - solna - klotrimazol - vaginaltablett - 100 mg

Canesten 500 mg Norge - norsk - Statens legemiddelverk

canesten 500 mg

bayer ab - solna - klotrimazol - vaginaltablett - 500 mg

Livostin 50 mikrog/ dose Norge - norsk - Statens legemiddelverk

livostin 50 mikrog/ dose

2care4 aps - levokabastinhydroklorid - nesespray, suspensjon - 50 mikrog/ dose

Canesten 1 % Norge - norsk - Statens legemiddelverk

canesten 1 %

farmagon - klotrimazol - krem - 1 %

Sutent Den europeiske union - norsk - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Sunitinib Accord Den europeiske union - norsk - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Ayvakyt Den europeiske union - norsk - EMA (European Medicines Agency)

ayvakyt

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinal stromal tumors - andre cytostatika, protein kinase hemmere - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Qinlock Den europeiske union - norsk - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.